WO2023058649A1 - ストレス改善剤 - Google Patents
ストレス改善剤 Download PDFInfo
- Publication number
- WO2023058649A1 WO2023058649A1 PCT/JP2022/037119 JP2022037119W WO2023058649A1 WO 2023058649 A1 WO2023058649 A1 WO 2023058649A1 JP 2022037119 W JP2022037119 W JP 2022037119W WO 2023058649 A1 WO2023058649 A1 WO 2023058649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stress
- skin
- active ingredient
- agent according
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a stress reliever, and more particularly to a stress reliever for improving rough skin caused by psychological stress or the like.
- Non-Patent Document 1 An example of evidence shows that (see, for example, Non-Patent Document 1).
- Cortisol suppresses the expression of keratin 10 (K10), filaggrin (FLG), and involucrin (INV) mRNA in normal human skin keratinocytes via glucocorticoid receptors, and increases intracellular oxidative stress.
- Ginkgo biloba extract containing flavonoids such as terpene lactones, kaempferol, and quercetin has been reported to restore cortisol-induced decreases in K10, FLG, and INV mRNA expression in normal human skin keratinocytes and three-dimensional artificial epidermis ( For example, see Non-Patent Document 2).
- Patent Document 1 discloses an ABCA12 gene expression promoter that contains an extract from the residue of pressing grapes as an active ingredient.
- ABCA12 which is one of the membrane transport proteins called transporters
- transporters is decreased by various internal and external factors, and when its function is disrupted, various abnormalities occur in the epidermis and the like. Therefore, agents that target the stratum corneum such as the skin and can directly promote the expression of the ABCA12 gene are not only pharmaceuticals and foods (including beauty and health-oriented food and drink), but also external preparations such as beverages and cosmetics. It is thought that it can be used for However, the active ingredient of the grape fruit-derived ABCA12 gene expression promoter has not yet been clarified.
- the problem to be solved by the present invention is to provide an active ingredient having a stress-relieving effect.
- the present inventors found that proanthocyanidins obtained from a specific purified fraction have skin rhythm-improving effects in human cultured cell lines. That is, the present invention includes the following embodiments.
- a stress reliever containing proanthocyanidin as an active ingredient containing proanthocyanidin as an active ingredient.
- the active ingredient is represented by the following formula (I):
- R 1 represents a methoxy group, a hydrogen atom or a hydroxy group
- R 2 is a hydrogen atom, a hydroxy group or the following formula (II):
- n represents an integer of 0 to 907.
- a proanthocyanidin represented by (1) or (2) which is a proanthocyanidin represented by (1) or (2).
- the stress-relieving agent according to (7), wherein the skin-related gene is ABCA12 and/or filaggrin.
- the stress ameliorating agent of the present invention it is possible to provide a stress ameliorating agent such as an action to ameliorate rough skin due to psychological stress.
- FIG. 1 shows the structural formulas of epicatechin and catechin, which are representative components of flavan compounds that constitute proanthocyanidins, and gallic acid, which is frequently ester-added to the hydroxyl group at the 3-position of the flavan ring.
- FIG. 2 is a fractionation diagram showing an outline of a method for fractionating a grape fruit extract by column chromatography.
- FIG. 3A is the result of reverse-phase HPLC analysis of the 70% acetone fraction purified in Example 1.
- FIG. FIG. 3B is the result of analyzing the 70% acetone fraction purified in Example 1 by GPC using a TSK-gel Super AW3000 column.
- FIG. 4 shows the relative expression levels of ABCA12 in human epidermal keratinocytes NHEK cultured in the presence or absence of the 70% acetone fraction purified in Example 1.
- FIG. 5 shows the relative expression levels of filaggrin in human epidermal keratinocytes NHEK cultured in the presence or absence of the 70% acetone fraction purified in Example 1.
- FIG. 6 shows the relative expression levels of Bmal1 in human epidermal keratinocytes NHEK cultured in the presence or absence of the 70% acetone fraction purified in Example 1.
- FIG. FIG. 7 shows the results of analyzing the 70% acetone fraction purified in Example 1 by GPC using a TSKgel SuperAW5000 column.
- the stress-relieving agent of the present invention contains proanthocyanidin as an active ingredient.
- the active ingredient "proanthocyanidins” refers to catechins, that is, polyphenols having a flavan skeleton as a basic unit. Examples of structural units thereof include flavan-3-ols such as catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, and epigallocatechin gallate.
- Fig. 1 shows the structural formulas of epicatechin and catechin, which are representative components of flavan compounds that constitute proanthocyanidins, and gallic acid, which is often esterified to the 3-position hydroxy group of the flavan ring.
- the 3-hydroxy group in this structural formula may form an ester (gallate) with gallic acid, and the hydroxy group at any site other than the 3-position forms a glycoside or methyl ether (methoxy).
- the main binding sites between the constituent units of proanthocyanidin include one position at positions 4 and 6 or positions 4 and 8, or two positions at positions 4 and 8 and oxygen at positions 2 and 7. It is not limited to these, and the steric configuration of these bonds is not particularly limited. In other words, proanthocyanidins, although there are many types, may have similar physiological activities due to the commonality that the carbon atoms in the flavan skeleton form oligomers by C—C bonds.
- proanthocyanidins obtained by polymerizing a specific monomer
- typical proanthocyanidins include propelargo, which is defined and classified according to the number of hydroxy groups on the B ring (see FIG. 1).
- Proanthocyanidin in the present invention is preferably procyanidin or prodelphinidin.
- the constituent units of “procyanidins” may be the same or different and may be selected from catechin, epicatechin, catechin gallate and epicatechin gallate.
- the constituent units of "prodelphinidin” may be the same or different and may be selected from gallocatechin, epigallocatechin, gallocatechin gallate and epigallocatechin gallate.
- Proanthocyanidin which is an active ingredient in the present invention, preferably has a molecular weight of 1000 to 190000 (the lower or upper limit of the molecular weight may be, for example, 5000, 41923.),
- the formula ( The compounds of I) include proanthocyanidins having a degree of polymerization n of 0 to 907. Since the active ingredient has a wide range of molecular weights, it can also be expressed as an average molecular weight. For example, in a molecular weight distribution curve obtained by gel permeation chromatography (GPC), when the molecular weight corresponding to the peak position is measured in terms of polystyrene, it has an average molecular weight of about 42,000.
- GPC gel permeation chromatography
- the average molecular weight may be expressed as a number average molecular weight value or a weight average molecular weight value, which will be described in detail in the examples below.
- the active ingredient has formula (I): (wherein R 1 represents a methoxy group (CH 3 O--), hydrogen atom (H--) or hydroxy group (HO--), R 2 represents a hydrogen atom, a hydroxy group or the following formula (II):
- n represents an integer from 0 to 907.
- n represents an integer from 0 to 907.
- the lower limit or upper limit of n can be set to 3, 9, 23, 73, 198, 339, for example.
- the above active ingredient of the present invention can be produced, for example, from plant materials such as grapes by organic solvent extraction and column chromatography purification. Alternatively, it may be produced by a chemical synthesis method using a known method. For example, catechin and epicatechin obtained from commercially available sources can be synthesized by multimerization (see, for example, Japanese Unexamined Patent Application Publication No. 2002-542240).
- the active ingredient more preferably has the following formula (IV): (Wherein, R 1 represents a methoxy group, a hydrogen atom or a hydroxy group, R 2 represents a hydrogen atom, a hydroxy group, or a functional group represented by formula (II) above; n represents an integer of 0 to 907; ) is a proanthocyanidin represented by Note that the lower limit or upper limit of n can be set to 3, 9, 23, 73, 198, 339, for example.
- the active ingredient according to the present invention can be extracted and purified from grapes, for example.
- the grape fruit extract used as a raw material for the stress ameliorator is preferably a fruit extract derived from the genus Vitaceae (Vitis), most preferably the genus Vitaceae (Vitis) ) is a fruit extract of Chardonnay. Or, in addition to Chardonnay, Vitis vinifera Niagara, Sauvignon Blanc, Riesling, Kerner, Cabernet Sauvignon, Cabernet Franc, Merlot Pinot Noir, or Wild Grape, or Vinifera hybrid Koshu, Muscat Berry A , Campbell Early, Muscat Alexandria, Kyoho, or Concord may be used.
- hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 3 carbon atoms such as methanol, ethanol, propanol and isopropanol; 4 polyhydric alcohols, and the like.
- the mixing ratio can be adjusted as appropriate, but from the results of Examples described later, extraction is performed with 30 to 50% 1,3-BG or 30 to 90% ethanol. is most preferred.
- the extraction is not particularly limited as long as the soluble components contained in the grape fruit (raw, fruit with skin, seeds in the fruit) can be eluted into the extraction solvent, and can be carried out according to the usual method.
- an extract can be obtained by immersing grapes in 2 to 10 times the amount (mass ratio) of an extraction solvent, extracting soluble components at room temperature, and filtering to remove extraction residues. If necessary, treatments such as dilution, concentration and drying may be carried out according to conventional methods.
- an adsorbent capable of adsorbing and eluting proanthocyanidins such as a styrene-divinylbenzene-based synthetic adsorption resin, anion exchange resin, octadecyl group chemically bonded silica gel (ODS), gel filtration resin (Toyopearl (registered trademark) HW- 40C, etc.) are used.
- Proanthocyanidins can be adsorbed by passing the above grape extract or the like through a column filled with these adsorbents, and after washing, fractionation and purification of proanthocyanidins can be performed by passing an appropriate eluate. can.
- a membrane separation method using a molecular weight fractionation membrane or the like can be used.
- ⁇ Stress improving agent and its effect ⁇ Stress improving agent and its effect>
- Psychological stress activates the hypothalamic-pituitary-adrenal axis and stimulates the production of stress hormones both locally and systemically. This results in decreased production of epidermal lipids and structural proteins, decreased hydration of the stratum corneum, and skin barrier dysfunction characterized by increased transepidermal water loss (TEWL).
- Cortisol which is secreted by psychological stress, is called hydrocortisone and is a hormone that maintains the homeostasis of the human body. Abnormal or excessive secretion of cortisol causes abnormal terminal differentiation of keratinocytes and affects skin conditions. is expected to give
- the stress alleviating agent of the present embodiment is preferably a stress alleviating agent for alleviating the subject's rough skin caused by psychological stress.
- the skin contains various genes whose expression is regulated by clock genes, for example, the ABCA12 protein gene and the moisturizing factor filaggrin gene FLG, which are important for the formation and maintenance of the skin barrier. It keeps a rhythm, and it repairs the skin periodically to keep it healthy. It is thought that when the genetic skin rhythm is weakened by psychological stress, the circadian rhythm of these skin-related genes is disturbed, thereby causing skin troubles such as dryness and rough skin.
- the stress reliever of the present embodiment cares for skin disorders by improving such skin rhythm. Therefore, a skin rhythm-improving agent refers to an agent that improves disturbance of the circadian rhythm of skin-related genes.
- a stress-reducing agent in one embodiment can be used for a subject having disturbances in the circadian rhythm of skin-related genes.
- Genes that control circadian rhythms include PER (PER1, PER2, etc.), CRY (CRY1, CRY2, etc.), BMAL (BMAL1, etc.), and CLOCK (CLOCK). These genes are known to be present in various animals such as humans and mice, and to be expressed in cells almost throughout the body. Skin-related genes regulated by these clock genes include, but are not limited to, ABCA12 and/or filaggrin.
- the Bmal1 gene is one of the clock genes and has the function of increasing the enzyme that makes fat cells. Bmal1 is thought to increase or decrease depending on the time of day in the body of mammals, with the lowest level around 3:00 pm and the highest level between 10:00 pm and 2:00 am.
- the ABCA12 gene is mainly expressed in the stomach and skin at embryonic day 18.5, and even after maturity, it is strongly expressed not only in the skin and stomach, but also in the heart, intestine, kidney, etc., and is also expressed in the brain, liver, and lung. Is recognized. In particular, hyperkeratosis of the epidermis and gastric mucosa is observed as a disorder in ABCA12 knockout mice.
- Filaggrin is a filament aggregating protein, and is a protein with a molecular weight of about 40 kDa that plays an important role in the formation of stratum corneum. In particular, it is known to play an important role in promoting epidermal differentiation and maintaining skin barrier function.
- Filaggrin is involved in various skin diseases, and it has been reported that mutation of the filaggrin gene is a major factor in the development of atopic dermatitis and ichthyosis vulgaris (Nature Genetics, 38, 441-446, 2006).
- oral composition The stress relieving agent of the present invention may be in the form of an oral composition as one embodiment.
- Oral compositions include, for example, beverages, foods, pharmaceuticals, and quasi-drugs.
- Specific examples of food and drink include vegetable juices, fruit juice drinks, soft drinks, beverages such as tea, instant noodles, soups, jellies, puddings, yogurt, cake premix products, confectionery, furikake, miso, soy sauce, sauces, and dressings.
- various general processed foods such as margarine, bread, cakes, cookies, chocolate, candies, gummies, gums and jellies, powders, granules, Pill-shaped, tablet-shaped, soft-capsule-shaped, hard-capsule-shaped, paste-shaped or liquid-shaped nutritional supplements, foods for specified health uses, functional foods, health foods, concentrated liquid diets, therapeutic foods for dysphagia, etc. can be done.
- the active ingredient of the present invention and known raw materials may be used, or a part of the known raw materials may be replaced with the active ingredient of the present invention and produced by a conventional method.
- the active ingredient of the present invention may optionally be added to glucose (glucose), dextrin, lactose, starch or processed products thereof, excipients such as cellulose powder, vitamins, minerals, oils and fats of animals, plants and fish, proteins ( (including proteins derived from animals, plants and yeast, hydrolysates thereof, etc.), carbohydrates, pigments, flavors, antioxidants, surfactants, other edible additives, and edible powders and extracts containing various nutritional functional ingredients.
- the stress-reducing agent of the present invention may be in the form of an external preparation for skin as one embodiment.
- the external preparation for skin according to the present embodiment is 1) pharmaceuticals, 2) quasi-drugs in a form suitable for use such as ampoules, capsules, powders, granules, liquids, gels, bubbles, emulsions, sheets, mists, and sprays.
- Topical or systemic external skin preparations for example, lotions, milky lotions, creams, ointments, lotions, oils, basic cosmetics such as packs, solid soaps, liquid soaps, facial cleansers such as hand washes, skin Cleansing agents, massage agents, cleansing agents, depilatories, depilatories, shaving agents, aftershave lotions, preshave lotions, shaving creams, foundations, lipsticks, blushers, eyeshadows, eyeliners, mascara, and other make-up cosmetics cosmetics, perfumes, nail preparations, nail enamels, nail enamel removers, poultices, plasters, tapes, sheets, patches, aerosols, etc.), 4) Medicinal or/and applied to the scalp and hair and cosmetic formulations (e.g., shampoos, rinses, hair treatment agents, pre-hair treatment agents, permanent liquids, hair dyes, hair styling agents, hair tonics, hair restorers, hair tonics, poultices, plaster agents, tape agents , sheet
- the amount of the active ingredient according to the present invention can be appropriately adjusted according to the formulation to be blended. , hereinafter the same), the range of 0.002 to 1.0% by mass for make-up cosmetics, and the range of 0.002 to 10.0% by mass for cleansing cosmetics.
- the solid content of the composition is in the range of 0.0001 to 5.0% by mass.
- the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
- the unit % of numerical values indicating the addition amount of various components means % by mass.
- Example 1 Purification of active ingredients from grape fruit extract European grape (Vitis vinifera L.) fruit (raw, fruit with skin/seeds in fruit) is extracted by adding 50% ethanol aqueous solution, A filtrate was obtained by filtration. The filtrate was dried by an evaporator and pulverized. 4.0 g of the powder was dissolved in 50% methanol and fractionated by carum chromatography according to the following procedure.
- Toyopearl (registered trademark) HW-40C column (inner diameter 2.2 cm, length 40 cm) was loaded with the methanol solution of the above extract, and various solvents shown in FIG. components were eluted. 50% methanol first, followed by 60% methanol, 70% methanol, a mixed solvent of methanol-water-acetone (70:20:10), a mixed solvent of methanol-water-acetone (70:10:20) and 70% After successive elution with acetone, 3.5 g, 81.0 mg, 68.4 mg, 60.8 mg, 58.6 mg and 118.3 mg of solid content were recovered, respectively. As shown in Test Example 1 described later, the 70% acetone-eluted fraction has the activity of promoting the expression of the Bmal1 gene in human epidermal cells, so we tried to identify the active ingredient by focusing on this fraction.
- FIGS. 3(a) and 3(b) The results of analysis of the 70% acetone-eluted fraction described above by reverse-phase HPLC or GPC under the conditions shown below are shown in FIGS. 3(a) and 3(b), respectively.
- ⁇ Calibration curve> TSKgel Standard Polystyrene Oligomer kit (Tosoh) was used as a standard, and analysis was carried out using standards having the following molecular weight ranges. Based on the results, a calibration curve was prepared by plotting the molecular weight on the horizontal axis and the retention time (min) on the vertical axis. The measured molecular weights of the standard products and the retention times (min) by GPC analysis are as follows. Molecular weight Retention time (min) 10200 7.40 17400 7.20 37900 6.90 96400 6.60 190000 6.29
- FIG. 7 shows the results of GPC analysis using the above 70% acetone eluted fraction.
- This fraction contained a polymer having a peak at a retention time of 6.880 minutes, and the molecular weight corresponding to the peak position was estimated to be 41,923 from the calibration curve.
- cDNA was synthesized using Takara Bio Inc.
- As a control (comparative control) a considerable amount of a solution equivalent to the solvent of the sample was used.
- the expression level of the gene was measured by a quantitative PCR method (polymerase chain reaction method). SYBR Premi Ex Taq (Takara Bio Inc.) was used for the quantitative PCR method.
- RPS18 As an internal standard, the expression level of RPS18, which is a housekeeping gene, was quantified, and the relative expression level ratio to RPS18 was calculated to obtain the Bmal1 gene relative expression level ratio.
- primers for PCR commercially available primers for RPS18 of Bmal1 (both QuantiTect Primers: Qiagen) were used.
- RNA was replaced with a KBM medium containing cortisol, and ABCA12 was cultured for 6 hours, while filaggrin was cultured for 22 hours.
- cDNA was synthesized using PrimeScript RT reagent Kit (Takara Bio).
- a control comparative control, no cortisol added
- a considerable amount of a solution equivalent to the solvent of the sample was used.
- the expression level of the gene was measured by a quantitative PCR method (polymerase chain reaction method). SYBR Premix Ex Taq (Takara Bio) was used for the quantitative PCR method.
- RPS18 As an internal standard, the expression level of RPS18, which is a housekeeping gene, was quantified, and the relative expression level ratio with respect to RPS18 was calculated as the relative expression level ratio of ABCA12 and filaggrin genes.
- Commercially available primers for ABCA12, filaggrin, and RPS18 (QuantiTect Primer: Qiagen or Perfect Real Time Primer: Takara Bio) were used as primers for PCR.
- FIGS. 4 to 6 The results are shown in FIGS. 4 to 6.
- FIG. 4 the control group is labeled as "control”.
- addition of cortisol reduced the expression level of ABCA12 relative to the control group to 0.62 (the group described as “cortisol” in FIG. 4), but addition of the purified sample reduced ABCA12 increased to 1.35 (group indicated as "cortisol + sample” in Fig. 4).
- addition of cortisol reduced the expression level of filaggrin relative to the control group to 0.61 (the group described as “cortisol” in FIG. 5), but addition of the purified sample reduced the expression level of filaggrin to 0.61. increased to 0.87 (group described as "cortisol + sample” in Fig. 5).
- FIG. 4 the control group is labeled as "control”.
- addition of cortisol reduced the expression level of ABCA12 relative to the control group to 0.62 (the group described as “cortisol” in FIG. 4), but addition of the purified sample reduced ABCA12
- cortisol decreased the expression level of BmalI relative to the control to 0.63 (the group labeled as “cortisol” in FIG. 6).
- the expression level relative value increased to 0.88 (group described as "cortisol + sample” in Fig. 6).
- "*" indicates that there is a statistically significant difference at p ⁇ 0.05 as a result of Dunnett's test.
- the stress ameliorating agent of the present invention can be used as a skin rhythm ameliorating agent that adjusts the circadian rhythm of skin-related genes. Therefore, the stress ameliorating agent of the present invention may be used as a cosmetic for improving rough skin of subjects caused by psychological stress.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023552898A JPWO2023058649A1 (cg-RX-API-DMAC7.html) | 2021-10-05 | 2022-10-04 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164041 | 2021-10-05 | ||
| JP2021-164041 | 2021-10-05 | ||
| JP2022-049554 | 2022-03-25 | ||
| JP2022049554 | 2022-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023058649A1 true WO2023058649A1 (ja) | 2023-04-13 |
Family
ID=85803488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/037119 Ceased WO2023058649A1 (ja) | 2021-10-05 | 2022-10-04 | ストレス改善剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2023058649A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023058649A1 (cg-RX-API-DMAC7.html) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095964A (ja) * | 2001-09-21 | 2003-04-03 | Toyo Shinyaku:Kk | 抗ストレス剤 |
| JP2003238425A (ja) * | 2002-02-18 | 2003-08-27 | Toyo Shinyaku:Kk | チロシナーゼ阻害剤および皮膚外用剤 |
| JP2004075587A (ja) * | 2002-08-14 | 2004-03-11 | Ij:Kk | プロアントシアニジン配合オタネニンジン抽出物製剤 |
| JP2005029486A (ja) * | 2003-07-09 | 2005-02-03 | Toyo Shinyaku:Kk | 皮膚改善組成物 |
| JP2009521475A (ja) * | 2005-12-23 | 2009-06-04 | マース インコーポレーテッド | 皮膚の保護および改善 |
| WO2013100003A1 (ja) * | 2011-12-28 | 2013-07-04 | サントリーホールディングス株式会社 | オリゴメリックプロアントシアニジンの精製方法、重合度の調整方法並びにヒアルロニダーゼ阻害剤及びコラゲナーゼ阻害剤 |
| JP2017222622A (ja) * | 2016-06-17 | 2017-12-21 | 一丸ファルコス株式会社 | Abca12遺伝子発現促進剤 |
-
2022
- 2022-10-04 JP JP2023552898A patent/JPWO2023058649A1/ja active Pending
- 2022-10-04 WO PCT/JP2022/037119 patent/WO2023058649A1/ja not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003095964A (ja) * | 2001-09-21 | 2003-04-03 | Toyo Shinyaku:Kk | 抗ストレス剤 |
| JP2003238425A (ja) * | 2002-02-18 | 2003-08-27 | Toyo Shinyaku:Kk | チロシナーゼ阻害剤および皮膚外用剤 |
| JP2004075587A (ja) * | 2002-08-14 | 2004-03-11 | Ij:Kk | プロアントシアニジン配合オタネニンジン抽出物製剤 |
| JP2005029486A (ja) * | 2003-07-09 | 2005-02-03 | Toyo Shinyaku:Kk | 皮膚改善組成物 |
| JP2009521475A (ja) * | 2005-12-23 | 2009-06-04 | マース インコーポレーテッド | 皮膚の保護および改善 |
| WO2013100003A1 (ja) * | 2011-12-28 | 2013-07-04 | サントリーホールディングス株式会社 | オリゴメリックプロアントシアニジンの精製方法、重合度の調整方法並びにヒアルロニダーゼ阻害剤及びコラゲナーゼ阻害剤 |
| JP2017222622A (ja) * | 2016-06-17 | 2017-12-21 | 一丸ファルコス株式会社 | Abca12遺伝子発現促進剤 |
Non-Patent Citations (2)
| Title |
|---|
| ICHIMARU PHARCOS CO., LTD.: "Chrono Chardy", FRAGRANCE JOURNAL, vol. 45, no. 10, 2017, pages 86 - 87 * |
| 濱田朋志・伊藤賢一, シャルドネ果実エキスによる体内時計に着目した皮膚バリア回復力の効果, Fragrance Journal. 2018, vol. 46, no. 2, pages 38-42, (HAMADA, Tomoji, ITO, Kenichi. Effect of chardonnay fruit extract on skin barrier recovery focused on circadian clock.) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023058649A1 (cg-RX-API-DMAC7.html) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024010247A (ja) | 皮膚化粧料、頭髪化粧料および飲食品 | |
| JP5226297B2 (ja) | 8−ヒドロキシリクイリチゲニン及び3’−ヒドロキシイソリクイリチゲニンの少なくともいずれかの製造方法 | |
| JP2017502087A (ja) | 化粧品組成物、皮膚科学組成物、または栄養化粧品組成物に使用するショ糖エステルを有効成分として含有する植物抽出物 | |
| KR101973639B1 (ko) | 콩잎 추출물을 함유하는 항산화용 조성물 | |
| JP2005029486A (ja) | 皮膚改善組成物 | |
| JP2022111283A (ja) | 新規コラーゲン再利用促進作用剤 | |
| JP5773111B2 (ja) | 皮膚の色素沈着を抑制する組成物およびその利用 | |
| JP6976014B1 (ja) | 新規ポリフェノール化合物 | |
| KR101904501B1 (ko) | 퓨코스테롤을 유효성분으로 포함하는 피부주름 개선 또는 피부탄력 증진용 화장료 조성물 | |
| JP2002302452A (ja) | ヒスタミン遊離抑制剤、サイクリックampホスホジエステラーゼ阻害剤、活性酸素消去剤およびラジカル消去剤 | |
| JP2005015364A (ja) | 抗酸化組成物、皮膚老化防止用組成物、抗炎症組成物及び脂質代謝改善用組成物 | |
| JP4822718B2 (ja) | 新規c−グリコシド化合物、コラーゲン産生促進剤、皮膚化粧料及び美容用飲食品 | |
| JP2021143131A (ja) | 抗老化剤、皮膚化粧料および経口組成物 | |
| KR101914441B1 (ko) | 퓨코스테롤을 유효성분으로 포함하는 피부 보습용 화장료 조성물 | |
| JP5143127B2 (ja) | 皮膚外用剤及び飲食品 | |
| JP5116328B2 (ja) | 皮膚外用剤及び飲食品 | |
| JP2003128569A (ja) | 皮膚外用剤および飲食品 | |
| KR20190033871A (ko) | 피부 노화 개선 복합 화장료 조성물 | |
| JP2024502775A (ja) | 皮膚改善用組成物 | |
| JP5132139B2 (ja) | 皮膚外用剤及び飲食品 | |
| KR101672841B1 (ko) | 피부 개선용 조성물 | |
| JP2006321730A (ja) | 抗酸化剤及び抗老化剤、並びに皮膚化粧料及び飲食物 | |
| KR101940055B1 (ko) | 콩잎 추출물을 함유하는 보습용 조성물 | |
| JP2007326799A (ja) | 活性酸素消去酵素発現促進剤 | |
| JP7070902B2 (ja) | 抗老化剤及びヒアルロン酸産生促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22878517 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023552898 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22878517 Country of ref document: EP Kind code of ref document: A1 |